美国镭学会关于前列腺癌根治性放疗后局限性前列腺内复发的检查与治疗的适当使用标准
美国镭学会泌尿生殖系统适当使用标准委员会针对前列腺癌根治性放疗后前列腺内局部复发(IPR-PC)的检查与局部挽救治疗制定循证推荐。多学科专家组基于文献综述与改良德尔菲法投票,建议采用PSMA PET和多参数MRI进行影像分期,局部挽救前需活检,推荐再程放疗以限制毒性,雄激素剥夺治疗仅短期用于放疗增敏。
要点
- 推荐PSMA PET和多参数MRI用于排除转移并明确局部复发范围。
- 局部挽救前必须活检,以避免对放射效应者过度治疗。
- 推荐再程放疗以限制毒性,激素治疗仅短期用于放疗增敏。
核心结论
- 本共识指南为IPR-PC的检查与治疗提供了循证指导,期待前瞻性证据进一步充实。
研究设计与样本
- 美国镭学会泌尿生殖系统适当使用标准委员会通过检索PubMed和Embase文献,由三名研究者评估总结四个主题,创建临床变异,多学科专家组投票并采用改良德尔菲法总结推荐。
主要发现
- 专家组认为应进行PSMA PET和多参数MRI影像分期,以排除转移性疾病并确定放射复发的局部范围。
- 局部挽救前需活检,以避免对影像学复发实为治疗效应的患者造成过度毒性。
- 考虑局部挽救优于单独非治愈性激素治疗,但共同决策至关重要。
- 推荐再程放疗方法以限制毒性;放疗挽救时激素治疗可能有助于放射增敏,但仅限短期,且经典雄激素剥夺治疗优于新型激素药物。
- 当通过多种影像和组织采样方式确认局灶复发时,应进行局灶挽救,尽管全腺体挽救的毒性似乎非常可耐受。
关键数值与推荐
- 多种放疗挽救方案存在,大多数可在六次或更少分次内完成。
- 本指南数据仅限于最初接受常规分次外照射放疗且复发检查在PSMA PET时代之前的个体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本指南数据仅限于最初接受常规分次外照射放疗且复发检查在PSMA PET时代之前的个体。
- 期待前瞻性证据进一步充实本指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Local intraprostatic radiorecurrence of prostate cancer (IPR-PC) can be associated with an aggressive natural history and impact long-term disease-specific survival. While appropriate local salvage intervention can be curative, best practices for workup and local salvage of intraprostatic recurrence are poorly defined. The American Radium Society (ARS) Genitourinary Appropriate Use Criteria Committee sought to develop evidence-based recommendations to address this gap. METHODS: PubMed and Embase were searched to retrieve a comprehensive set of relevant peer-reviewed articles on four topics relevant to the workup and treatment of IPR-PC. The literature was evaluated and summarized by three investigators, and clinical variants were created for each of the four topics. The ARS Genitourinary AUC multidisciplinary expert panel voted on the most appropriate procedures for each variant, and a modified Delphi approach was used to summarize recommendations. KEY FINDINGS AND LIMITATIONS: The panel concluded that radiographic staging via prostate-specific membrane antigen positron emission tomography (PSMA PET) and multiparametric magnetic resonance imaging should be performed to exclude patients with metastatic disease and identify the local extent of radiorecurrence. Biopsy is required before local salvage to avoid excessive toxicity in patients whose radiographic recurrence represents a treatment effect. Consideration of local salvage is preferred in lieu of noncurative hormonal manipulation alone, although shared decision-making is critical. Salvage reirradiation approaches are recommended to limit toxicity. Hormonal therapy may be beneficial for radiosensitization when radiotherapeutic salvage is pursued, but only of short duration, and classic androgen deprivation therapies are preferred over novel hormonal agents. Focal salvage should be pursued when confidence in focal recurrence can be confirmed via multiple radiographic and tissue sampling modalities, although the toxicity associated with whole-gland salvage appears to be very tolerable. Several radiotherapeutic salvage regimens exist, most of which can be carried out in six or fewer fractions. The data informing this guideline are limited to individuals initially treated with conventionally fractionated external beam radiotherapy and with workup for recurrence before the PSMA PET era. CONCLUSIONS AND CLINICAL IMPLICATIONS: This consensus guideline provides evidence-based guidance on the appropriate procedures for workup and treatment of IPR-PC. Prospective evidence to enrich these guidelines is eagerly anticipated. PATIENT SUMMARY: We summarize evidence for the best workup and treatment for patients with local recurrence of prostate cancer after radiotherapy. A panel of experts evaluated previous studies and voted on the procedures that should be performed and those that should be avoided. This guideline is a useful tool for helping doctors to discuss the best treatment options that maximize the chance of cure while minimizing side effects.
引用
- Valle LF, Jiang T, Rosenbloom A, et al. American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy. Eur Urol Oncol. 2024. PMID: 39307608. doi:10.1016/j.euo.2024.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。